Search

Displaying results 911 - 920 of 10000 in total
  1. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.

    Products: Atosiban Aguettant 6,75 mg/0,9 ml Injektionslösung, TRACTOCILE (7.5 MG/ML SOLUTION FOR INJECTION)
  2. Drug

    Edetate copper disodium

    go.drugbank.com/drugs/DB14599
    Experimental

    Synonyms: Copper versenate, Copper disodium edetate
  3. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    [A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. … [A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and

    Products: BOTEMIB 2.5 MG, BOTEMIB 1.0 MG
  4. Drug

    Medazepam

    go.drugbank.com/drugs/DB13437
    Investigational

    Mixtures: TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 20 ADET, TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 40 ADETProducts: NOBRAL 10 MG KAPSÜL, 20 ADET, NOBRAL 10 MG KAPSÜL, 250 ADET
  5. Drug

    Levobupivacaine

    go.drugbank.com/drugs/DB01002
    ApprovedInvestigationalWithdrawn

    Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the t...

    Products: CHIROCAINE 5.0 MG/ML, CHIROCAINE INJECTION 5 mg/ml
  6. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

    Categories: Immunoglobulin GProducts: YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA
  7. Drug

    Flumazenil

    go.drugbank.com/drugs/DB01205
    ApprovedInvestigational

    imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex

    Products: ANEXATE INJECTION 0.5 mg/5 ml, LANEXAT® AMPOLLAS 0.5 MG /5 ML
  8. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex

    Products: RAPAMUNE 1 MG 100 FILM DRAJE, RAPAMUNE 0.5 MG TABLET ,100 ADET
  9. Drug

    Pentazocine

    go.drugbank.com/drugs/DB00652
    ApprovedVet approved

    It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)

    Products: Pentazocine-Fresenius 30 mg/ml injection, Talwin - Liq 30mg/ml
  10. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a ...

    Products: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)